Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 2/20 | 0.44 |
| ▸ | ELANE | P08246 | 9/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.40 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
| ▸ | XIAP | P98170 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5987813 | 1.00 | KCNH2 (0.44) | KCNH2ELANECYP3A4CYP2C9CYP2C19 | |
| SCHEMBL3269632 | 0.91 | ELANE (0.44) | KCNH2ELANECYP3A4CYP2C9CYP2C19 | |
| SCHEMBL3268486 | 0.91 | ELANE (0.44) | KCNH2ELANECYP3A4CYP2C9CYP2C19 | |
| SCHEMBL8524556 | 0.90 | KCNH2 (0.43) | KCNH2ELANECYP3A4CYP2C9CYP2C19 | |
| SCHEMBL13014698 | 0.90 | ELANE (0.51) | KCNH2ELANECYP3A4CYP2C9NR1I2 | |
| SCHEMBL10299169 | 0.90 | ELANE (0.51) | KCNH2ELANECYP3A4CYP2C9NR1I2 | |
| SCHEMBL18930080 | 0.88 | KCNH2 (0.40) | KCNH2ELANECYP3A4CYP2C9CYP2C19 | |
| SCHEMBL18913820 | 0.88 | ACE (0.50) | KCNH2 | |
| SCHEMBL21641823 | 0.88 | ACE (0.50) | KCNH2 | |
| SCHEMBL21641824 | 0.88 | ACE (0.50) | KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230285378-A1 | Anti-Viral Compounds | ABBVIE INC. (US) | 2023-09-14 | — | — | US | disclosed |
| US-20190015402-A1 | Anti-Viral Compounds | ABBVIE INC. (US) | 2019-01-17 | — | — | US | disclosed |
| US-10039754-B2 | Anti-viral compounds | ABBVIE INC. (US) | 2018-08-07 | — | — | US | disclosed |
| US-10028937-B2 | Anti-viral compounds | ABBVIE INC. (US) | 2018-07-24 | — | — | US | disclosed |
| US-20170157105-A1 | Anti-Viral Compounds | ABBVIE INC. (US) | 2017-06-08 | — | — | US | disclosed |
| US-20170157104-A1 | Anti-Viral Compounds | ABBVIE INC. (US) | 2017-06-08 | — | — | US | disclosed |
| US-9586978-B2 | Anti-viral compounds | ABBVIE INC. (US) | 2017-03-07 | — | — | US | disclosed |
| US-20120172290-A1 | Anti-Viral Compounds | ABBOTT LABORATORIES (US) | 2012-07-05 | — | — | US | disclosed |
| US-20110207699-A1 | Anti-Viral Compounds | Abbott Labaoratories (US) | 2011-08-25 | — | — | US | disclosed |
| US-20110092415-A1 | Anti-Viral Compounds | Abbott Labaoratories (US) | 2011-04-21 | — | — | US | disclosed |
| US-20100317568-A1 | Anti-Viral Compounds | Abbott Labaoratories (US) | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317568-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | KCNH2 4523/4885ELANE 986/4885CYP3A4 1792/4885 |
| US-10028937-B2 | Anti-viral compounds | HAVCR2, EIF2AK2, MAVS | KCNH2 4523/4885ELANE 986/4885CYP3A4 1792/4885 |
| US-20230285378-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | KCNH2 4523/4885ELANE 986/4885CYP3A4 1792/4885 |
| US-20170157105-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | KCNH2 4523/4885ELANE 986/4885CYP3A4 1792/4885 |
| US-20110092415-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | KCNH2 4523/4885ELANE 986/4885CYP3A4 1792/4885 |
| US-20170157104-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | KCNH2 4523/4885ELANE 986/4885CYP3A4 1792/4885 |
| US-20110207699-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | KCNH2 4523/4885ELANE 986/4885CYP3A4 1792/4885 |
| US-20190015402-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | KCNH2 4523/4885ELANE 986/4885CYP3A4 1792/4885 |
| US-20120172290-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | KCNH2 4523/4885ELANE 986/4885CYP3A4 1792/4885 |
| US-10039754-B2 | Anti-viral compounds | HAVCR2, EIF2AK2, MAVS | KCNH2 4523/4885ELANE 986/4885CYP3A4 1792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.